ArticleScientific reports2025
Metabolomics and network analysis reveal the mechanism of Salvia miltiorrhiza bunge extract in ameliorating cognitive dysfunction in sleep-deprived rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms of natural compounds in treating inhalation anesthesia-induced cognitive dysfunction.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sleep deprivation (SD) causes learning memory and cognitive impairment. Salvia miltiorrhiza Bunge (Danshen, DS), a medicinal plant in the family Labiatae, has been traditionally used for sleep-related disorders. Previous studies have shown that DS can ameliorate SD-induced cognitive impairment. However, the underlying mechanisms for its pharmacological effects remain unclear. This study aimed to evaluate the protective effects and mechanisms of DS extract against cognitive impairment in SD rats. UPLC-QTOF/MS was used to analyze DS extracts. The SD model was constructed utilizing a modified multi-platform aquatic sleep deprivation procedure that lasted 21 days. The Morris water maze test (MWM), hematoxylin and eosin (H&E) staining, and enzyme-linked immunosorbent assay (ELISA) were used to assess learning and memory ability, hippocampus injury, and serum inflammation, respectively. An integrated strategy of serum metabolomics combined with network analysis was used to explore the potential mechanisms by which DS exerts pharmacological effects. Molecular docking and experiments were used for further validation. UPLC-QTOF-MS/MS identified 32 diterpenoids in DS extract. The results showed that DS (1.35 and 2.70 g/kg) significantly improved spatial learning and memory abilities in SD rats while also reducing hippocampus pathological damage and serum inflammation. Serum metabolomics showed that DS modulated 26 differential metabolites, mainly involved in Glycerophospholipid metabolism, Glycerolipid metabolism, Phosphatidylinositol signaling system, and One carbon pool by folate. Network analysis screened 145 putative targets for DS to alleviate SD-induced cognitive impairment, involved in inflammation regulation and metabolic modulation. Integrated analyses of metabolomics and network analysis indicated that PIK3CA was a key target for DS's regulatory effects, primarily engaged in the regulation of phosphatidylinositol phosphate metabolism. Validation experiments revealed that all eight components of DS extracts had a higher binding ability with PIK3CA, and DS restored the SD-induced abnormal expression of PIK3CA. Our study provides new insights into the development of DS as a dietary supplement for treating SD-induced cognitive impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.